Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 345,621
  • Shares Outstanding, K 108,345
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -132,070 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.86
  • Price/Sales 23.46
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 190.86% (+33.84%)
  • Historical Volatility 169.38%
  • IV Percentile 60%
  • IV Rank 14.57%
  • IV High 815.52% on 04/09/25
  • IV Low 84.30% on 09/02/25
  • Expected Move (DTE 5) 0.72 (22.65%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 14
  • Volume Avg (30-Day) 431
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 22,356
  • Open Int (30-Day) 20,254
  • Expected Range 2.47 to 3.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.17
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +22.22%
on 01/16/26
4.89 -34.76%
on 01/20/26
+0.48 (+17.71%)
since 01/13/26
3-Month
2.25 +41.77%
on 11/14/25
4.89 -34.76%
on 01/20/26
+0.87 (+37.50%)
since 11/13/25
52-Week
1.05 +203.81%
on 04/10/25
4.89 -34.76%
on 01/20/26
+0.99 (+45.00%)
since 02/13/25

Most Recent Stories

More News
Aclaris Therapeutics to Participate in Two February Healthcare Conferences

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended...

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...

ACRS : 3.19 (-5.06%)
Aclaris: Q3 Earnings Snapshot

Aclaris: Q3 Earnings Snapshot

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target;...

ACRS : 3.19 (-5.06%)
Aclaris Therapeutics to Participate in Three November Healthcare Conferences

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...

ACRS : 3.19 (-5.06%)
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and Aclaris Therapeutics (ACRS – Research Report) with...

ACRS : 3.19 (-5.06%)
BMY : 60.74 (+1.47%)
Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Aclaris Therapeutics today. The company’s shares opened today at $1.85.Elevate Your Investing Strategy: Take advantage of TipRanks...

ACRS : 3.19 (-5.06%)

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 3.57
2nd Resistance Point 3.49
1st Resistance Point 3.34
Last Price 3.19
1st Support Level 3.10
2nd Support Level 3.02
3rd Support Level 2.87

See More

52-Week High 4.89
Fibonacci 61.8% 3.42
Last Price 3.19
Fibonacci 50% 2.97
Fibonacci 38.2% 2.52
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar